132560-11-3 Usage
General Description
1,8-dimethyl-3-(2-phenylethyl)-3,7-dihydro-1H-purine-2,6-dione is a chemical compound with a complex molecular structure. It is a derivative of purine and contains two methyl groups, a phenylethyl group, and a dihydro-1H-purine-2,6-dione core. 1,8-dimethyl-3-(2-phenylethyl)-3,7-dihydro-1H-purine-2,6-dione is commonly known as Theophylline, which is a bronchodilator used to treat conditions such as asthma, bronchitis, and emphysema. Theophylline works by relaxing the muscles in the airways and increasing the lung capacity, making it easier to breathe. It is also known for its stimulant effects on the central nervous system, which can improve alertness and physical performance. Theophylline is available in various formulations, including oral tablets, capsules, and injections, and is typically administered under medical supervision due to its narrow therapeutic range and potential for side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 132560-11-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,2,5,6 and 0 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 132560-11:
(8*1)+(7*3)+(6*2)+(5*5)+(4*6)+(3*0)+(2*1)+(1*1)=93
93 % 10 = 3
So 132560-11-3 is a valid CAS Registry Number.
132560-11-3Relevant articles and documents
Structure-activity relationships in a series of xanthine derivatives with antibronchoconstrictory and bronchodilatory activities
Merlos,Gomez,Vericat,Bartroli,Garcia-Rafanell,Forn
, p. 653 - 658 (2007/10/02)
Thirty-one 1,3,7,8-substituted xanthine derivatives have been synthesized and evaluated for bronchodilator and anti-bronchoconstrictory activities in in vitro tracheal relaxation and in vivo bronchospasm inhibition models. Activity tests have been complemented with phosphodiesterase inhibition and toxicological data. Structure-activity relationships are discussed. Compound 21 (1,3-diisobutyl-8-methylxanthine) has been selected for further pharmacological development because of its good activity profile and favourable therapeutic index, which is 14- and 38-fold greater than that of theophylline and IBMX, respectively.
